Non-Postoperative Acute Pain Market Poised for Significant Expansion by 2034, Amid FDA Approvals and Innovative Therapeutic Pipeline
The non-postoperative acute pain treatment market is positioned for substantial growth, driven by a strategic shift from traditional opioid therapies to advanced multimodal analgesia approaches and novel treatment options. Key pharmaceutical companies, including Vertex Pharmaceuticals, H. Lundbeck, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others, are spearheading innovation to address the significant unmet needs in non-postoperative acute pain management.
DelveInsight's report titled " Non-Postoperative Acute Pain Market Insight, Epidemiology, and Market Forecast - 2034" provides a thorough analysis of trends in the non-postoperative acute pain market. It covers market drivers and challenges, historical and projected epidemiology, the current treatment landscape, and emerging therapies across the 7MM, which include the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The non-postoperative acute pain market size in the 7MM was valued at USD 3.6 billion in 2023, with significant growth expected at a notable CAGR during the forecast period (2024-2034). This growth is primarily fueled by rising prevalence, enhanced diagnostic capabilities, and the introduction of novel therapeutic options.
Download the Non-Postoperative Acute Pain Market Forecast Report to understand which factors are driving the Non-Postoperative Acute Pain market @ Non-Postoperative Acute Pain Market Trends.
The US represents the largest share of the non-postoperative acute pain market, with approximately 50 million incident cases reported in 2023. Epidemiological data reveal that moderate to severe cases contributed approximately 60% to the total diagnosed cases in the 7MM. Furthermore, pain cases related to migraine and cluster headaches constituted approximately 40% of total diagnosed cases in 2023 in the US, highlighting the significant burden of headache disorders within the acute pain spectrum.
Discover evolving trends in the Non-Postoperative Acute Pain patient pool forecasts @ Non-Postoperative Acute Pain Epidemiological Analysis.
The current non-postoperative acute pain treatment paradigm has undergone substantial transformation in recent years, with a notable shift away from opioid-based therapies toward multimodal analgesia (MMA) models. NSAIDs continue to play a crucial role in pain management, recognized for their ability to decrease opioid consumption by approximately 50%, positioning them as first-line medications for mild-to-moderate pain. Despite the availability of numerous generic NSAIDs following patent expirations, branded innovations continue to emerge, offering improved delivery systems and enhanced efficacy profiles.
Among the recently approved medications, ELYXYB (celecoxib) by Scilex Holding (NASDAQ: SCLX) represents a breakthrough as the first and only ready-to-use oral solution designed for fast and long-lasting migraine relief with COX-2 selectivity. Other significant market entrants include ZAVZPRET (zavegepant) by Pfizer (NYSE: PFE), the first calcitonin gene-related peptide (CGRP) receptor antagonist available as a nasal spray, and NURTEC ODT by Pfizer/Biohaven Pharmaceutical (NYSE: BHVN), expanding treatment options for patients suffering from acute migraines.
Furthermore, in January 2025, SYMBRAVO (AXS-07) was approved by the FDA for the acute treatment of migraine with or without aura in adults. The drug is a novel oral, rapidly-absorbed, multi-mechanistic investigational medicine combining MoSEIC meloxicam and rizatriptan for the acute treatment of migraine, with patent protection extending to 2036.
The non-postoperative acute pain therapeutic pipeline shows significant promise, with several advanced candidates in late-stage development. VYEPTI (eptinezumab) by H. Lundbeck A/S (CPH: HLUN-B), a monoclonal immunoglobulin G1 antibody that specifically binds to human calcitonin gene-related peptide, is currently in Phase III development for cluster headache following its FDA approval for migraine prevention in adults in February 2020.
Satsuma Pharmaceuticals (NASDAQ: STSA) is developing STS101, a dihydroergotamine nasal powder, which has demonstrated significant efficacy in providing sustained pain freedom and reduced need for rescue medication. Other notable pipeline candidates include Naltrexone Cetaminophen by Allodynic Therapeutics, further diversifying the therapeutic landscape
Discover evolving trends in the Non-Postoperative Acute Pain treatment landscape @ Non-Postoperative Acute Pain Recent Developments.
According to DelveInsight's specialists in the field, emerging therapies like STS101 DHE nasal powder have shown significant effectiveness in providing sustained pain relief with lower rescue medication requirements. The FDA's approval of therapies like EMGALITY for reducing the frequency of episodic cluster headache attacks represents a milestone in addressing previously undertreated acute pain conditions. These developments signal a positive trajectory for patients seeking more effective and targeted pain relief options.
Despite therapeutic advances, challenges remain in the non-postoperative acute pain landscape, including the need for improved diagnostic accuracy, personalized treatment approaches, and enhanced accessibility to innovative therapies. As the field continues to evolve, increasing focus on biomarker-guided therapy selection and integration of non-pharmacological approaches alongside pharmaceutical interventions will likely reshape treatment strategies, offering improved outcomes for the millions affected by acute pain conditions worldwide.
The integration of emerging digital health technologies and improved understanding of pain neurobiology is expected to further revolutionize acute pain management, moving toward more personalized, effective, and safer treatment paradigms that significantly enhance patient quality of life while minimizing the risks associated with traditional pain management approaches.
Table of Contents
1. Key Insights
2. Executive Summary of Non-Postoperative Acute Pain
3. Non-Postoperative Acute Pain Competitive Intelligence
4. Non-Postoperative Acute Pain: Market Overview at a Glance
5. Non-Postoperative Acute Pain: Disease Background and Overview
6. Patient Journey
7. Non-Postoperative Acute Pain Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Postoperative Acute Pain Unmet Needs
10. Key Endpoints of Non-Postoperative Acute Pain Treatment
11. Non-Postoperative Acute Pain Marketed Products
12. Non-Postoperative Acute Pain Emerging Therapies
13. Non-Postoperative Acute Pain: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Non-Postoperative Acute Pain
17. KOL Views
18. Non-Postoperative Acute Pain Market Drivers
19. Non-Postoperative Acute Pain Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
6 hours ago
- CTV News
Shooting leaves 1 dead, 11 hurt on a North Carolina street during a house party
In this image taken from WSOC video, various police and officials gather outside a community after a mass shooting, Sunday, June 1, 2025, in Hickory, a city in Catawba County, N.C. (WSOC via AP) HICKORY, N.C. — Gunfire erupted around a house party in western North Carolina early Sunday and one person was killed and 11 others were hurt, some with gunshot wounds and others with injuries from fleeing the shooting in a usually quiet residential neighborhood, sheriff's deputies said. Authorities said at least 80 shots were fired in the shooting that began at about 12:45 a.m. People reported running, ducking for cover and scrambling to their cars for safety. Hours later Sunday, law enforcement had made no arrests and was seeking tips from the public in the case. A statement from the Catawba County Sheriff's Office said a 58-year-old man, Shawn Patrick Hood, of Lenoir, was killed, the oldest of the victims who ranged in age from as young as 16. It said seven of the injured remained hospitalized late Sunday, though updates on their conditions were not immediately released. One of the victims was previously reported in critical condition. Authorities believe there was more than one shooter, a sheriff's spokesperson said. The agency said it was asking for people who attended the party to contact the office. Sheriff's office Maj. Aaron Turk aid at a news conference that the shooting occurred in a normally quiet neighbhoord in southwest Catawba County about 7 miles (11 kilometers) south of the city of Hickory. He said that about two hours before the shooting, someone in another home complained about noise from the party. He added that deputies responded but that investigators don't believe the noise complaint was the motivation for the shooting. Turk said the crime scene spanned several properties along a neighborhood road, covering about two acres (0.8 hectares), and included outdoor and indoor areas. The North Carolina State Bureau of Investigation and the Hickory Police Department are investigating the shooting. The FBI is also assisting in the case with a specialized evidence response team, officials said.
CTV News
11 hours ago
- CTV News
1 dead, 11 others injured in North Carolina overnight shooting
In this image taken from WSOC video, various police and officials gather outside a community after a mass shooting, Sunday, June 1, 2025, in Hickory, a city in Catawba County, N.C. (WSOC via AP) HICKORY, N.C. — One person is dead and at least 11 others were injured in a mass shooting during a party at a western North Carolina residence, according to the Catawba County Sheriff's Office. The shooting took place at about 12:45 a.m. Sunday in Hickory, a city in Catawba County. One victim is in critical condition and ten others are in serious condition at the hospital, according to the Sheriff's Office. The North Carolina State Bureau of Investigation and the Hickory Police Department are investigating. The Federal Bureau of Investigation is also assisting. No arrests have been made and the number of shots fired is not yet known. The Sheriff's Department has not released the victims' names or ages, but Major Aaron Turk said at a press conference the street is usually quiet. The Associated Press
Globe and Mail
12 hours ago
- Globe and Mail
Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?
The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 to an estimated $381.5 billion by 2033. Two pharmaceutical giants, Eli Lilly (LLY) and Novo Nordisk (NVO), dominate this market. Both companies have created GLP-1 receptor agonists that have transformed obesity treatment: Eli Lilly's Mounjaro (tirzepatide) and Zepbound, and Novo Nordisk's Ozempic and Wegovy (semaglutide). Let's see which company is ahead of the game and has the best investment case right now. The Case for Eli Lilly Stock Valued at $684 billion, Eli Lilly has been a standout performer in the global pharmaceutical industry. Aside from its obesity treatments, it is well-known for developing groundbreaking treatments for autoimmune diseases, cancer, diabetes, Alzheimer's, and other conditions. LLY stock has fallen 6.4% year-to-date, compared to the S&P 500 Index's ($SPX) gain of 0.1%. Recently, Eli Lilly announced that Zepbound has demonstrated superior efficacy in weight loss compared to Novo Nordisk's Wegovy. The SURMOUNT-5 trial found that participants on Zepbound lost more body weight and waist circumference over 18 months than those on Wegovy. This superior efficacy is due to tirzepatide's dual action as a GLP-1 and GIP agonist, which boosts weight-loss effects. Financially, Eli Lilly reported a 45% increase in revenue in the first quarter of 2025, reaching $12.73 billion, thanks to strong sales from Mounjaro and Zepbound. Adjusted earnings increased 29% to $3.34 per share during the quarter. Mounjaro, in particular, saw a 113% year-over-year sales increase to $3.8 billion worldwide. Zepbound's sales increased threefold from the same quarter last year. Aside from the success of its weight-loss drugs, the company's non-incretin portfolio includes successful oncology, neuroscience, and immunology drugs, which are driving growth. The company anticipates 2025 revenue to be in the range of $58 billion to $61 billion, representing year-over-year growth of 28% to 35%. Eli Lilly has taken proactive measures to capitalize on the weight-loss drug boom. The company has handled supply chain issues more effectively than Novo Nordisk, resulting in improved product availability. Last year, the company launched Mounjaro in all major European markets and provided early stage access in China. In order to increase accessibility, the company has formed partnerships with telehealth providers and launched direct-to-consumer initiatives. Furthermore, Lilly's investment in orforglipron, an oral GLP-1 receptor agonist, has yielded encouraging results in Phase 3 studies. Patients lost significant weight, and the convenience of a pill form could transform obesity treatment, making it more accessible and appealing to a larger patient base. On Wall Street, Eli Lilly has earned an overall ' Strong Buy ' rating. Of the 25 analysts who cover the stock, 20 rate it a 'Strong Buy,' two a 'Moderate Buy,' and three recommend a 'Hold.' The average analyst price target of $991.46 suggests a 34.7% increase from current levels. Furthermore, the Street-high estimate of $1,190 implies that the stock could rally by up to 62% over the next year. The Case for Novo Nordisk Stock Valued at $311.7 billion, Novo Nordisk is a Denmark-based pharmaceutical company specializing primarily in diabetes care, obesity treatment, and other chronic disease therapies. Novo Nordisk's Ozempic and Wegovy have been instrumental in the company's growth. However, Eli Lilly's weight loss drugs have demonstrated superior efficacy, challenging Novo Nordisk's market dominance. Novo's stock has fallen nearly 20% year to date, compared to the overall market. In the first quarter of 2025, Novo Nordisk reported earnings per share of 6.53 DKK, in line with analyst expectations. Sales rose 18% year on year to 78.08 billion DKK, led by a 15% rise in Ozempic sales and an 83% increase in Wegovy sales. Despite these gains, the company faces significant challenges due to increased competition and shifting market dynamics. As a result, Novo Nordisk lowered its full-year guidance, projecting 2025 sales growth of 13% to 21%, significantly lower than Lilly's projections. Analysts who cover the stock expect Novo's revenue to grow by 25.5%, followed by earnings growth of 26%. While Eli Lilly's drugs have demonstrated superior efficacy, according to Leerink Partners analyst David Risinger, most people are unaware that Zepbound outperforms Wegovy. As a result, Novo continues to hold 65% of the market, while Lilly holds 34%. However, this may soon change. On Wall Street, Novo Nordisk stock has earned an overall ' Moderate Buy ' rating. Of the 18 analysts who cover the stock, eight rate it a 'Strong Buy,' seven say it is a 'Hold,' one says it is a 'Moderate Sell,' and two suggest a 'Strong Sell.' The average analyst price target of $101.93 suggests a 44% increase from current levels. Furthermore, the Street-high estimate of $160 implies that the stock could rally by up to 128% over the next year. The Verdict: Eli Lilly Takes the Lead Both Eli Lilly and Novo Nordisk continue to strengthen their incretin portfolios. However, based on clinical efficacy, market performance, strategic initiatives, and leadership stability, Eli Lilly currently has a competitive advantage over Novo Nordisk in the weight-loss drug market. Overall, Eli Lilly stock represents a better long-term investment.
